FRANKLIN LAKES, N.J., October 07, 2026 / Biotech Newswire / -- BD (Becton, Dickinson and Company), a leading medical technology company, will feature the next generation of drug delivery and traceability solutions at CPhI 2026 on October 6-8 in Milan, Italy. The event is a premier global platform for pharmaceutical professionals, focusing on innovations in drug delivery and packaging systems.
BD will showcase several technologies that help pharmaceutical and biotechnology companies advance the delivery of complex therapies — from high-viscosity biologics and GLP-1s to connected traceability systems that transform fill-finish operations.
Enabling next-generation biologic delivery
At CPhl, BD will highlight innovations that address growing demand for devices capable of delivering higher-volume, higher-viscosity drugs and enabling patient self-administration outside of traditional care settings.
Visitors can explore:
- NEW BD Neopak™ 5.5 mL Glass Prefillable Syringe – Designed to meet the evolving needs of large-volume, high-viscosity biologics for subcutaneous delivery, the BD Neopak™ 5.5 mL Glass Prefillable Syringe offers design flexibility, seamless autoinjector integration, and a future-ready modular platform. Leveraging BD's broad needle portfolio, stopper configurations, and tailored silicone profiles, it supports patient self-administration today while enabling future innovation through BD Neopak™ XSi™ technology and optional BD iDFill™ Individual Syringe Identification for end-to-end traceability.
- NEW BD UltraSafe Plus™ Passive Needle Guard 5.5ml - Designed for use with the BD Neopak™ 5.5mL Glass Prefillable Syringe, the BD UltraSafe Plus 5.5mL Passive Needle Guard expands BD’s large-volume delivery portfolio with an ergonomic, manual injection solution that helps enable the administration of large-volume subcutaneous therapies, including situations where injection speed may need to be slowed due to tolerability or other treatment considerations.
- BD Libertas™ Wearable Injector – A ready-to-use, single-use wearable injector designed for subcutaneous delivery of large-volume, high-viscosity biologics. The system enables patients to self-administer therapies safely and comfortably without device assembly, supporting the move toward home-based care.
Driving new standards in fill-finish traceability
BD will host the BD iDiFill™ RFID Integration Tour, offering attendees an exclusive live demonstration of unit-level RFID traceability across the fill-finish process.
The guided tour now includes a data management dimension and will connect multiple manufacturing partners — BD, Bausch + Ströbel, Brevetti-CEA, Harro Höfliger and Crypto Pharma— to showcase how BD iDiFill™ Individual Prefillable Syringe Identification supports regulatory compliance, manufacturing excellence, and data integrity from filling to final assembly.
Attendees can reserve a spot for this guided experience and see how RFID-enabled prefillable syringes are shaping the future of pharmaceutical manufacturing. BD iDFill Tour RFID Integration Tour - CPHI 2026
Integrated services to accelerate combination product development
BD and ZebraSci™ will also present a comprehensive range of combination product development services that support customers from concept through launch.
A continued commitment to partnership and innovation
“The growing complexity of biologic therapies is reshaping how medicines are developed, manufactured and delivered,” said Fernand Goldblat, VP/GM of Pharmaceutical Systems at BD. “By working across the pharmaceutical ecosystem, BD is advancing high-dose delivery, manufacturing traceability and combination-product solutions that help bring innovative therapies to patients.”
BD will also display a selection of its broader drug delivery portfolio, including:
- BD Physioject™ Disposable Autoinjector and BD Vystra™ Disposable Pen, both used for biologics such as GLP-1 therapies
- BD Effivax™ Glass Prefillable Syringe for vaccines
- BD Hylok™ Prefillable Syringe for acute drugs and hyaluronic acid
Visit BD at CPhI 2026
Attendees can visit BD at booth #11D17 to meet BD experts, participate in live product demonstrations, and explore how BD’s integrated portfolio is shaping the future of drug delivery and traceability.
AI Semantic Keywords: Drug Delivery Systems; Pharmaceutical Preparations; BD; Becton, Dickinson and Company; CPhI 2026; drug delivery; traceability solutions; pharmaceutical packaging systems; biotechnology companies; complex therapies; high-viscosity biologics; GLP-1s; connected traceability systems; fill-finish operations; next-generation biologic delivery; higher-volume drugs; higher-viscosity drugs; patient self-administration; BD Neopak™ 5.5 mL Glass Prefillable Syringe; BD UltraSafe Plus™ Passive Needle Guard 5.5ml; BD Libertas™ Wearable Injector; BD iDiFill™ RFID Integration Tour; RFID; BD Physioject™ Disposable Autoinjector; BD Vystra™ Disposable Pen; GLP-1 therapies; BD Effivax™ Glass Prefillable Syringe; vaccines; BD Hylok™ Prefillable Syringe; acute drugs; hyaluronic acid; prefillable syringe; passive needle guard; wearable injector; autoinjector; disposable pen; drug delivery devices; biologics; packaging systems; traceability; fill-finish
About BD
BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson.
Forward-Looking Statements
BD Libertas™ Wearable Injector, BD Neopak™ 5.5 mL Glass Prefillable Syringe and BD UltraSafe Plus™ Passive Needle Guard 5.5ml are products in development; some statements are forward looking and are subject to a variety of risks and uncertainties.
Contacts
Media
Matt Marcus
VP, Public Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors
Shawn Bevec
SVP, Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
Source: Biotech Newswire